Allotex’s Post

As part of our Spotlight on tissue engineering, we surveyed our audience to dive deeper into the current industry landscape, investigating topics such as cell sourcing, culturing, scaffolding and biocompatibility. Want to find out if you agree with your peers? View the infographic >>> https://hubs.ly/Q02r1pmq0

#AMWC2024 Day 2 Today was more exciting than yesterday. I think second day is the best day in a 3-day conference. We continued to discuss the role of #advisory, #consulting, #data, and #primaryresearch and #secondaryresearch in the #aesthetics space with our partners in the industry. We believe there is deep value for everyone on both the sides of that table. Other highlights include, the opportunity to use advanced polymer syringes in aesthetics, mid-tier companies wanting to be trendsetters instead of followers, growing companies with positive cash flows are expanding geographies, MDR will limit private labeling in HA fillers space, reducing number of filler players in Europe, and exosomes space is gathering strong momentum which requires detailed validation in the future. Sumit Mehta #aesthtics #exosomes #marketresearch

Proud to have 4RealSim being interviewed by Dassault Systèmes to discuss the EU SimInSitu - In-silico Development- and Clinical-Trial-Platform project. SimInSitu aims to develop sophisticated in-silico methods to predict the short- and long-term behavior of in-situ tissue-engineered heart valves (TEHV) by combining advanced tissue remodeling algorithms with a personalized virtual heart modeling approach. The method will be specifically developed to predict the complex transformation process of biodegradable heart valves from the initially synthetic scaffold into a fully remodeled and functional valve.

🚀 ALine is rising to the Microfluidics Rapid Manufacture Challenge with innovative solutions. 🔬 Moving from proof of concept to early product launch can be a daunting task, but at ALine, we are ready to tackle the challenge head-on. 💡 Our solution involves rapid scale-up with high quality and the flexibility to make design and material changes as needed. We have the expertise to convert batch processes into flow processes to meet critical timelines. 🏆 ALine has demonstrated over the last 20 years, through numerous client programs, including companies such as DxNow, Epicore and Interlink, our ability to deliver high-quality components and assembled products for our customers. 🌐 Learn more about Microfluidic Rapid Manufacture at ALine: https://lnkd.in/g8bmueV9 #Innovation #Manufacturing #RapidManufacturing #InnovativeSolutions #Innovation #Teamwork #Microfluidics #Diagnostics #Research #Mission #ALineInc #ALine #MicrofluidicTechnology #MicrofluidicDevices

🚀 Exciting News! 🚀 We are thrilled to present our latest video showcasing the innovative 𝐄𝐦𝐮𝐥𝐬𝐢𝐨𝐧 𝐂𝐨𝐥𝐥𝐞𝐜𝐭𝐢𝐨𝐧 𝐟𝐫𝐨𝐦 𝐨𝐧𝐞 𝐃𝐨𝐥𝐨𝐦𝐢𝐭𝐞 𝐓𝐞𝐥𝐨𝐬 𝐂𝐡𝐢𝐩! 🎥 ✨ In this video, you'll get an exclusive look at the groundbreaking 𝐃𝐨𝐥𝐨𝐦𝐢𝐭𝐞 𝐓𝐞𝐥𝐨𝐬 𝐒𝐲𝐬𝐭𝐞𝐦 - a scale-out system designed for production environments, which is precisely controlled to produce monodisperse droplets on a large scale, revolutionizing microfluidic applications. 🔬 𝐊𝐞𝐲 𝐅𝐞𝐚𝐭𝐮𝐫𝐞𝐬: - High precision fluid control - Production-scale monodisperse droplet generation - Each Telos chip contains 7 junctions for parallel processing - Capable of running up to 10 chips concurrently for expanded production Whether you're in research, diagnostics, drug discovery, or any field requiring precise fluid control, our Telos system offers unparalleled performance and versatility. https://lnkd.in/eBKhEYCa #Dolomite #Telos #Microfluidics #Innovation #Technology #FluidControl #ProductionScale #DrugDiscovery #Diagnostics

Let's discover the semi-finalists of the Prix Strategis! 🚀 Our third semi-finalist is TissueLabs ! TissueLabs is at the cutting edge of biofabrication technology, with a transformative approach to creating bioartificial organs and tissues. Their flagship innovation, MatriXpec™, emulates tissue-specific microenvironments for enhanced 3D cell culture, marking a significant leap beyond conventional biomaterials. MatriXpec™ is meticulously engineered to direct cell behavior and differentiation, enabling the formation of intricate three-dimensional vascular networks. Complementing their vision, they offer state-of-the-art 3D bioprinters, TissueStart™ and TissueRay™. These sophisticated tools, in synergy with their specialized biomaterials, facilitate the biofabrication of 15 distinct tissues and organs, paving the way for groundbreaking research, pre-clinical developments, and future therapeutic applications. Their innovation is fortified by a robust patent-pending portfolio, encompassing both their revolutionary biomaterials and 3D bioprinters. If you want to learn more about them : https://lnkd.in/dicJQSXP

Unlock the potential of #osteoinductive and #osteoconductive biomaterials in treating bone defects. With innovative testing methods and co-culture models, advancements in bone healing are on the rise. Discover how these cutting-edge solutions are shaping the future of #tissueengineering: https://bit.ly/3OdHeEU

𝗛𝗶𝗴𝗵𝗹𝗶𝗴𝗵𝘁𝘀 𝗳𝗿𝗼𝗺 𝗕𝗶𝗼-𝗜𝗧 𝗪𝗼𝗿𝗹𝗱 𝗖𝗼𝗻𝗳𝗲𝗿𝗲𝗻𝗰𝗲 & 𝗘𝘅𝗽𝗼 𝟮𝟬𝟮𝟰! Reflecting on an exciting week, we share some key moments from our time in Boston: Mario Torchia's poster presentation "𝘋𝘦𝘮𝘰𝘤𝘳𝘢𝘵𝘪𝘻𝘪𝘯𝘨 𝘵𝘩𝘦 𝘜𝘴𝘦 𝘰𝘧 𝘔𝘰𝘥𝘦𝘭𝘪𝘯𝘨 𝘢𝘯𝘥 𝘚𝘪𝘮𝘶𝘭𝘢𝘵𝘪𝘰𝘯 𝘸𝘪𝘵𝘩 𝘐𝘯𝘚𝘪𝘭𝘪𝘤𝘰𝘛𝘳𝘪𝘢𝘭𝘴' 𝘉𝘪𝘰𝘴𝘪𝘮𝘶𝘭𝘢𝘵𝘪𝘰𝘯 𝘗𝘭𝘢𝘵𝘧𝘰𝘳𝘮" sparked discussions on our #biosimulation platform. 🤝 Our team (Michael Eckstut, MaryAnne Rizk, Ph.D. and Mario Torchia) engaged with passionate professionals like Nimita Limaye across the #lifesciences, #pharmaceuticals and #healthcare sectors, further fueling our mission to revolutionize #drugdevelopment through the use of #insilico technology. 📘 We also had the chance to feature the book "𝘛𝘰𝘸𝘢𝘳𝘥 𝘎𝘰𝘰𝘥 𝘚𝘪𝘮𝘶𝘭𝘢𝘵𝘪𝘰𝘯 𝘗𝘳𝘢𝘤𝘵𝘪𝘤𝘦" co-edited by our CEO Luca Emili, highlighting a consolidated set of industrial practices that render the development and use of #insilicotrials solutions easier and reliable. 🔽 Download the book and get in touch to find out how companies are already leveraging #modelingandsimulation to accelerate #medical innovation, reducing time and costs of specific R&D activities by up to 90%—all while upholding the highest standards of #patientsafety: https://lnkd.in/d-s6PY-f

🚨 miDiagnostics Secures €30M Series D Funding to Advance Sterility Testing for Biopharma! 🧬💡 Belgium-based MiDiagnostics has raised €30M in its Series D funding round, led by Thermo Fisher Scientific and supported by existing investors like Alychlo, VMF Invest, and Pamica. With this new funding, MiDiagnostics will: 🔬 Accelerate development of a revolutionary sterility test for batch release in biopharma using its cutting-edge qPCR technology. 🌍 Leverage Thermo Fisher’s expertise to bring innovative solutions to market. 💻 MiDiagnostics’ tech combines: ✔️ A nanofluidic processor on a silicon chip ✔️ A compact reader for rapid analyte measurement MiDiagnostics CEO Katleen Verleysen stated: "This funding will enable us to expedite our development efforts and revolutionize sterility testing in the biopharma sector.” Notably, MiDiagnostics is also behind a SARS-CoV-2 breath test developed in 2021, showcasing its commitment to pushing boundaries in diagnostics. 🔗 Collaborations with imec and The Johns Hopkins University highlight the firm’s strong foundation in innovation. #Diagnostics #Biopharma #FundingNews #Innovation #ThermoFisher #LifeSciences #MiDiagnostics #PCRTechnology

In Martin Hall's most recent research note on Tissue Regenix Group, he looks at the continued strong performance of the life sciences company which has seen strong growth in 7 consecutive reporting periods, leading to TRX becoming EBIT profitable in 1H'24. The double-digit sales growth during this period and increased cash generation will enable TRX to forge ahead with Phase 2 on its reinvestment strategy by expanding processing and manufacturing capacity. The additional capacity has the potential to add $50m of sales, leading to total potential sales of $100m. Download Martin's note here to learn more about TRX's growth story - https://lnkd.in/e4nkPeQx * Investment risks are highlighted in the note #lifesciences #medicaldevices #investments #investing #capitalmarkets